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Following the online publication of this article, the authors noted that the following funding information needed to be included: This work was supported through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Also, [Table 3](#tbl3){ref-type="table"} requires correction of few numbers. The correction has already been made to the html version of the article.

###### Characteristics of bispecific antibodies generated for acute myeloid leukemia

                                                               *MW (kDa)*   *Affinity (*K~*D*~*) (n[M]{.smallcaps})*   *EC*~*50*~ *p[M]{.smallcaps}*                 *Clone*                         
  ----------------------------------------------------------- ------------ ------------------------------------------ -------------------------------- ----------------------------------- --------- ----------------------------------------------------------------
  CD33 × CD3 BiTE AMG330^9^                                        55                         5.1                                    \-                                 8                    0.4-3   \-
  CD33 × CD3 scBsTaFv^17,146,147^                                  60                          \-                                   0.1                              10-100                   15     DRB2 (CD33)
  CD33 × CD16 chemically conjugated^23^                            \-                          \-                                    \-                                \-                     \-     251 (CD33), 3G8 (CD16)
  CD16 × 33 BiKE^148--150^                                         55                      20 (scFv)                                 \-                                \-                     \-     NM3E2 (CD16)
  CD33 × CD16 × CD33 sctb^29^                                      90                      45.1 ± 4.3                                \-                              7.9±1.1                1.8-18   K132 (CD33), 3G8 (CD16)
  CD33 × CD16 × CD19 sctb^30^                                      90                       49 ± 5.2                                 \-                           CD33 (29±1.9)             7.2 ± 2  K132 (CD33), 3G8 (CD16)
  CD123 × CD16 × CD33 sctb^31^                                     90                      21.7 ± 1.8                                \-                 CD33 (17.8±2.2), CD123 (18.8±0.9)   21-118   K132 (CD33), 3G8 (CD16), CD123 (from phage (151)
  CD123 × CD3 BIF^152,153^                                        140                          10                                0.01-0.05                             0.1                    10     12F1 (CD123), UCHT1 (CD3)
  CD3 × CD123 DART^42^                                             59                        9 ±2.3                                  \-                            0.13 ±0.01                0.17    7G3 (CD123)
  CD123 × CD16 bsscFv^151^                                         60                        49 ± 5                                  \-                             4.5--101                211-364  3G8 (CD16), CD123 (from phage (151))
  CD15 × CD64 chemically conjugated^54^                            \-                          \-                                    \-                                \-                     \-     PM81 (CD15), 32 (CD64)
  CD33 × CD64 chemically conjugated^32,34^                         \-                          \-                                    \-                                \-                     \-     H22 (CD64), 251 (CD33)
  CD16 × CD33 chemically conjugated^23^                            \-                          \-                                    \-                                \-                     \-     3G8 (CD16), 251 (CD33)
  CD3 × CD33 modular retargeting system^19^                        \-                          \-                                   0.1                                \-                     \-     MT-301 (CD3), DRB2 (CD33)
  CD33 × CD3 BiFab^a,68^                                         \~100                         \-                                    7                  Similar to their parental clones    25-445   Mutated hM195 (CD33), and UCHT1 (CD3)
  Anti-CD3 Fab\' × anti-CD13Fab\' chemically conjugated^51^     100-110                        \-                                    \-                                \-                     \-     OKT3 (CD3), My7 (CD13)
  CD30 × CD16A TandAb^60^                                       105--110                      0.39                                  17.2                               9.3                  35 800   LSIV21 (CD16), HRS-3 (CD30)
  CD30 × CD16A bispecific diabody^60^                              60                          35                                   17.2                               194                  751 000  LSIV21 (CD16), HRS-3 (CD30)
  WT1 × CD3 BiTE^46,47^                                            \-                          \-                                    \-                                0.2                    \-     ESK1 (WT1), L2K (CD3)
  CD20 × CD47 DVD-Ig                                               \-                          \-                                CD47 (3.1)                       CD47 (48-60)                \-     2B8 (CD20), B6H12.2 (CD47)
  CLL1 × CD3 BiFab^a,68^                                         \~100                         \-                                   6.1                 Similar to their parental clones    2.1-41   Mutated 1075.7 (CLL1), and UCHT1 (CD3)
  FLT3 × CD3 BiTE^71^                                              \-                          \-                                    \-                                \-                     \-     4G8 (FLT3), UCHT1 (CD3)
  FLT3 × CD3 Fabsc^71^                                             87                          \-                                    \-                                \-                     \-     4G8 (FLT3), BV10 (FLT3), UCHT1 (CD3), OKT3 (CD3), BMA031 (CD3)
  VEGF × Ang-2 CrossMab^80,81^                                     \-                          \_                      Bevacizumab (\<0.1)Ang-2 (0.2)    Bevacizumab (\<0.1)Ang-2 (0.2)       \-     Bevacizumab=humanized A.4.6.1 (VEGF) and LC06 (Ang-2)

BiFab antibodies were generated by conjugating the antigen-binding fragments (Fab) of two antibodies using bio-orthogonal chemical linkers.
